|Bid||82.11 x 1000|
|Ask||109.96 x 800|
|Day's Range||90.67 - 91.79|
|52 Week Range||60.65 - 93.67|
|PE Ratio (TTM)||40.17|
|Earnings Date||Oct 31, 2018 - Nov 5, 2018|
|Forward Dividend & Yield||0.50 (0.55%)|
|1y Target Est||93.29|
Zoetis Inc. (ZTS) today announced that it has agreed to sell $1.5 billion of senior notes, consisting of $300 million aggregate principal amount of floating rate senior notes due 2021, $300 million aggregate principal amount of 3.250% senior notes due 2021, $500 million aggregate principal amount of 3.900% senior notes due 2028 and $400 million aggregate principal amount of 4.450% senior notes due 2048, in an underwritten public offering. Zoetis intends to use the net proceeds to repay $500 million drawn under the 364-day revolving credit facility entered into on July 27, 2018, repay $500 million issued under its commercial paper program, and for general corporate purposes. Barclays Capital Inc., Citigroup Global Markets Inc., J.P. Morgan Securities LLC, Merrill Lynch, Pierce, Fenner & Smith Incorporated and MUFG Securities Americas Inc. are acting as joint book-running managers of the underwriters.
Moody's Investors Service ("Moody's") assigned a Baa1 rating to the proposed senior unsecured notes offering of Zoetis Inc. ("Zoetis"). There are no changes to Zoetis' existing ratings including the Baa1 senior unsecured rating and the Prime-2 commercial paper rating. Proceeds from the notes offerings will be used to repay short term debt that was used in financing the acquisition of Abaxis, Inc. and for general corporate purposes.
Sector rotation in this market continues, and the agribusiness and chemical industries within the materials sector look to be heating up. While their performance on a relative basis is lackluster, on an absolute basis, there are several setups offering reward/risk scenarios skewed in our favor. First, let's take a structural look at the VanEck Vectors Agribusiness ETF ( MOO), which contains exposure to chemical stocks, as there is no exchange-traded fund (ETF) dedicated to that industry.
In the second quarter of 2018, Merck’s (MRK) Animal Health business generated revenues of $1.1 billion compared to $955.0 million in the second quarter of 2017, reflecting ~14% growth on a year-over-year (or YoY) basis and 2% growth sequentially. In the second quarter of 2018, in the US market and international markets (outside the U.S. markets), Merck’s Animal Health business generated revenues of $311.0 million and $779.0 million, respectively, reflecting ~15% and ~14% YoY growth.
Apple leads five top stocks to watch that are in or near buy range and showing relative strength. CSX, Ross Stores, Zoetis and PerkinElmer are also triggering a bullish technical signal.
Prices had been trading sideways to slightly higher since March but a big rally Thursday pushed share prices to new highs. In this daily bar chart of ZTS, below, we can see Thursday's upside breakout. The daily On-Balance-Volume (OBV) line has been in a neutral or flat trend from late February and shows some softness the past month.
Elanco is Eli Lilly & Co.’s (LLY) animal health business. Elanco reported revenues of $792.1 million in the second quarter, representing 1.0% YoY (year-over-year) growth from $784.8 million in the second quarter of 2017. The chart below shows Elanco’s revenues since the first quarter of 2017.
The animal health market continues to be strong, and so is the outlook. Here are several plays on the space and why you should make them.
Like Benno Dorer, the CEO of Clorox, Zoetis' CEO Juan Ramón Alaix also comes on Mad Money. What shocked me when I dug down is what stood out as the biggest growers in its panoply of products: new products for companion animals. Now, the humanization of pets has been a continual theme of Mad Money for ages.
Apple surged to a $1 trillion market cap Thursday, but shares are extended. Tesla stock soared, but is well off a buy point. Focus on top stocks in a buy zone or setting up.
Teva Pharmaceutical stock plunged on its mixed second quarter results Thursday as full-year guidance came in light and fellow drugmaker Zoetis beat quarterly views.
Zoetis second-quarter 2018 results exceed both earnings and sales estimates. The company completes the acquisition of Abaxis, Inc.
Zoetis (ZTS) delivered earnings and revenue surprises of 8.45% and 2.21%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
The Parsippany, New Jersey-based company said it had net income of 79 cents per share. Earnings, adjusted for non-recurring gains, came to 77 cents per share. The results exceeded Wall Street expectations. ...
On Thursday, Zoetis (NYSE: ZTS ) will release its latest earnings report. Check out Benzinga's report to understand the earnings report's implications. Earnings and Revenue Zoetis EPS is expected to be ...
Per Barron's, these four stocks are standouts in this regard: health insurer UnitedHealth Group Inc. ( UNH), animal drug and vaccine producer Zoetis Inc. ( ZTS), semiconductor maker Nvidia Corp. ( NVDA) and payments processor Mastercard Inc. ( MA). Dividend growth rates are the average annual increases recorded over the past 5 years.
NEW YORK , July 31, 2018 /PRNewswire/ -- Triumph Bancorp Inc. (NASD: TBK) will replace Abaxis Inc. (NASD: ABAX) in the S&P SmallCap 600 effective prior to the open of trading on Monday, August 6 . S&P ...
Zoetis Inc. (ZTS) today announced the completion of the acquisition of Abaxis, a leader in the development, manufacture and marketing of diagnostic instruments for veterinary point-of-care services for US $83 per share in cash, or approximately $2.0 billion in aggregate. The acquisition, which was first announced on May 16, follows the satisfaction of all conditions to the closing, including the receipt of the approval of the acquisition by Abaxis shareholders at a shareholder meeting earlier today.
We expect Zoetis (ZTS) to throw more light on its Abaxis acquisition plans and other pipeline updates during second-quarter 2018 earnings call.
Futures Steady With Inflation Data on Tap, Fed Decision Tomorrow Stock futures are floating slightly higher this morning as the Personal Consumption Expenditures index data are due at 8:30am Eastern. Market expectations for the Core PCE, excluding food and energy prices, are for a 2% year over year rise. Anything significantly above that and we […] The post Market Morning: PCE Inflation, California Burning, Lab Grown Mouse Meat & Apple Earnings appeared first on Market Exclusive.
Short interest is extremely low for ZTS with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting ZTS. ETFs that hold ZTS had net inflows of $657 million over the last one-month.